Author Archive for: Beth
Entries by Beth Zalcman
AN INTRO TO SBIR
Part VI: Funding Opportunities These can be divided into 2 categories: solicited and unsolicited Unsolicited opportunities, also known as investigator-initiated or omnibus solicitations, or parent announcements are when investigators submit a solicitation with no specific solicitation. Many NIH institutes participate in the parent announcements. Approximately, two-thirds of all awards are unsolicited; even if you can’t […]
AN INTRO TO SBIR
Part V: Standard Due Dates for SBIR/STTR Applications The due dates for SBIR/STTR applications are cyclic: January 5 April 5 June 5 September 5 It takes ~2 months from submission until review and score. It can take another 3-4 months to be awarded. The NIH has been working on reducing the amount of time it […]
AN INTRO TO SBIR
Part IV: The NIH Phased Program There are 3 phases to SBIR/STTR awards. Phase I: to establish the technical merit, feasibility, and commercial potential of the proposed R&D efforts. The awards to both SBIR/STTR generally do not exceed $225K; though for SBIR this amount is for 6 months, and for STTR, this amount is for […]
AN INTRO TO SBIR
Part III: Eligibility Only US-based small businesses are eligible and must meet all of the following criteria at the time of award to get funded: For-profit organization Located in the US No more than 500 employees, including affiliates At least 51% US-owned and controlled by individuals who are citizens or permanent residents SBIR-only: Be a […]
AN INTRO TO SBIR
Part II: What’s the difference between SBIR and STTR? SBIRs are intended to fuel growth in the private sector and commercialization of innovations derived from federally funded R&D. This is done by funding small businesses seeking to commercialize innovative biomedical technologies. STTRs are intended to stimulate a “partnership of ideas and technologies” between small businesses […]
AN INTRO TO SBIR
Part I: What are SBIRs/STTRs? The total pocket of non-dilutive funding from the US government is around $50B annually. Most of the non-dilutive funding for life sciences, biotech and medtech comes from the National Institutes of Health (NIH) – around $28B in 2018 (against a total budget of $37B). Through the 24 funding institutes at […]